December 29, 2022 – The COVID-19 pandemic has heightened public awareness about molecular diagnostics. While PCR testing has been the cornerstone of molecular diagnostics for years, there are a wide variety of molecular diagnostic solutions that provide faster results than traditional PCR-based methods. However, these solutions may not provide the same level of reliability and accuracy as PCR tests which analyze the presence of the actual virus’ genetic material with high sensitivity and are the most effective means of detecting active infection.
“When sick patients come in the hospital, you want the most sensitive test, and that’s a PCR test,” said Dr. Dave Persing, Chief Medical and Technology Officer for Cepheid, a molecular diagnostics company based in Sunnyvale, Calif. “You don’t want to miss a case and then find out later that the patient is positive for COVID-19. Having a sensitive test at admission is important.”
Dr. Persing continues, “In the past, molecular testing made sacrifices in sensitivity and performance in exchange for speed. But today, Cepheid’s combination of best-in-class laboratory quality accuracy along with speed is unique.”
Additionally, Cepheid has a long and storied role in the evolution of molecular diagnostics in responding to global public health threats and emergencies over past two decades including anthrax in 2001, H1N1 influenza in 2009, Ebola in 2014, and Covid-19 in 2020.
Read more in the latest issue of The Journal of Healthcare Contracting.